Of note, hnRNPA3 and eIF4H are reduced in C9orf72-FTD/ALS patient brain (Mori et al., 2016), and therefore supplementation may provide therapeutic benefit, whereas components of the PAF1C complex are upregulated and the PKR pathway is aberrantly activated in disease and thus inhibition of these pathways may normalize levels (Goodman et al., 2019a; Zu et al., 2020). The gene discussed is HNRNPA3; the disease is frontotemporal dementia.